Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine.

Nabin K ShresthaPatrick C BurkeAmy S NowackiSteven M Gordon

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

The 2023-2024 formula COVID-19 vaccine given to working-aged adults afforded modest protection overall against COVID-19 before the JN.1 lineage became dominant, and less protection after.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
systematic review
respiratory syndrome coronavirus
drug delivery
single cell
human milk
preterm birth